Decentralized Clinical Trials Among Topics Slated For CDER Guidance In 2020
Executive Summary
US FDA's to-do list also includes guidances on development of non-opioid analgesics and cannabis compounds, evaluation of generic therapeutic equivalence, and pediatric product development.
You may also be interested in...
Decentralized Trials Guidance May Reflect US FDA’s Lessons Learned During COVID-19
Work on guidance that was originally expected in 2020 continues as the agency and industry learn more about the utility and spectrum of decentralized trials as a result of the novel coronavirus pandemic.
COVID-19 And IP: Companies Are 'Taking A Chance' Sharing Clinical Trial Details
While companies often keep clinical trial endpoints a secret, FDA's Peter Marks notes that may not be the case with COVID-19 vaccines; CDER's Patrizia Cavazzoni says agency may expand de-centralized trials.
FDA Looks Ahead To Complex Product-Specific Guidances
The agency offers a glimpse of its regulatory agenda, although several have been carried over through multiple list updates.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: